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Abstract
Background: Acute exacerbations of COPD are a major cause of morbidity, mortality and
hospitalisation. Respiratory viruses are associated with the majority of exacerbations but a causal
relationship has not been demonstrated and the mechanisms of virus-induced exacerbations are
poorly understood. Development of a human experimental model would provide evidence of
causation and would greatly facilitate understanding mechanisms, but no such model exists.
Methods: We aimed to evaluate the feasibility of developing an experimental model of rhinovirus
induced COPD exacerbations and to assess safety of rhinovirus infection in COPD patients. We
carried out a pilot virus dose escalating study to assess the minimum dose of rhinovirus 16 required
to induce experimental rhinovirus infection in subjects with COPD (GOLD stage II). Outcomes
were assessed by monitoring of upper and lower respiratory tract symptoms, lung function, and
virus replication and inflammatory responses in nasal lavage.
Results:  All 4 subjects developed symptomatic colds with the lowest dose of virus tested,
associated with evidence of viral replication and increased pro-inflammatory cytokines in nasal
lavage. These were accompanied by significant increases in lower respiratory tract symptoms and
reductions in PEF and FEV1. There were no severe exacerbations or other adverse events.
Conclusion:  Low dose experimental rhinovirus infection in patients with COPD induces
symptoms and lung function changes typical of an acute exacerbation of COPD, appears safe, and
provides preliminary evidence of causation.
Background
Chronic Obstructive Pulmonary Disease (COPD) is pre-
dicted to become the 3rd leading cause of death worldwide
by 2020 [1]. Much of the morbidity, mortality and health
care costs of COPD are associated with acute exacerba-
tions[2]. Treatments for COPD exacerbations are only
partially effective, have significant side effects and do not
address specific mechanisms involved in its pathogenesis.
Bacterial infections are associated with around 50% of
COPD exacerbations and although studies have demon-
strated clinical improvement with antibacterial therapy,
their therapeutic impact is still disappointing[3,4]. Recent
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studies report symptoms of virus infection precede two
thirds of COPD exacerbations[5] and viruses can be
detected in the majority [5-8]. The majority of viruses
detected in these studies were rhinoviruses, however a
causal relationship between rhinovirus infection and
COPD exacerbations has not been established.
Development of new therapies for COPD will require
understanding mechanisms of virus-induced lower airway
inflammation to identify molecular therapeutic targets.
However, little is known about the pathophysiological
changes occurring in the lower respiratory tract during
COPD exacerbations. In asthma experimental rhinovirus
infection has provided valuable insights into the mecha-
nisms linking virus infections to asthma exacerbation [9-
14]. The development of an experimental model of rhino-
virus-induced COPD exacerbation would be a major step
forward in COPD research by providing evidence of a
causal relationship between rhinovirus infection and
exacerbations, thereby providing impetus to efforts to
develop antiviral therapy[15,16]. Such a model would
also permit detailed studies of the pathogenesis of COPD
exacerbation in a manner not possible with naturally
occurring exacerbations. Experimental rhinovirus infec-
tion has never previously been carried out in patients with
COPD and its effect in this patient group is not known.
Safety is the primary concern in all such studies and par-
ticularly in relation to COPD as, compared with the mild
asthmatics, COPD patients are older, have more severe
airway obstruction and less reversibility and are smokers
or ex-smokers.
To investigate the feasibility and safety of developing a
model of COPD exacerbation and to investigate a causa-
tive role of virus infection we conducted a virus dose-esca-
lating pilot study in which we inoculated subjects with
COPD with rhinovirus 16 (RV16) and assessed changes in
upper and lower respiratory tract symptoms, lung func-
tion, and virus replication and inflammatory responses in
nasal lavage.
Methods
Pilot study design
As there is no precedent for such a study in COPD
patients, we designed this pilot study based on published
literature and previous experience with challenge studies
in normal volunteers and asthmatics. We elected to carry
out a virus dose-escalating study to determine the lowest
dose of virus that would induce colds in COPD patients.
Studies in asthmatic volunteers have inoculated between
100 and 10,000 virus units (tissue culture infective doses
50% [TCID50])[9,15]. As this inoculum has not been pre-
viously administered to COPD patients and its safety in
this patient group was unknown, an initial low dose of 10
TCID50 of RV16 was selected as the starting dose. We
developed a protocol whereby 5 subjects would be inocu-
lated and if the criteria for completion were not achieved
then 100 TCID50 would be inoculated into a subsequent
group of 5 subjects, followed by 5-fold increasing doses of
virus until the criteria for completion of the study were
satisfied. The protocol defined criteria for completion of
the study were:
1. Colds in ≥ 50% of subjects according to clinical criteria
and ≥ 80% evidence of infection according to virological
criteria (detecting virus in nasal secretions or a four-fold
or greater serum neutralizing antibody response in serum)
and:
2. An acute exacerbation of COPD (as defined using the
lower respiratory tract scoring system) in ≥ 80% of sub-
jects and:
3. No severe exacerbations or other adverse events.
Study subjects
Subjects were recruited from the Chest Clinic, St Mary's
Hospital, London, UK and from local General Practices
and fulfilled the inclusion and exclusion criteria in Table
1. Ethical approval was obtained from the Local Research
Table 1: Inclusion/exclusion criteria for study subjects.
• Age 40–75 years.
• No history of asthma or allergic rhinitis.
• Not atopic on skin testing.
• Current or ex-smokers with at least 20 pack years cumulative smoking.
• Post-bronchodilator FEV1 ≤ 80% and ≥ 50% predicted for age and height.
• Post-bronchodilator FEV1/FVC ratio less than 70% predicted.
• β-agonist reversibility of less than 12%.
• Absence of a current or previous history of bronchiectasis, carcinoma of the bronchus or other significant respiratory disease (other than 
COPD).
• Absence of significant systemic disease.
• No COPD exacerbation or respiratory tract infection within the previous 8 weeks.
• Serum antibodies to rhinovirus 16 at screening in a titre <1:2.
• No treatment with oral, inhaled or nasal topical steroids, long-acting β-agonists or tiotropium in the previous 3 months.Respiratory Research 2006, 7:116 http://respiratory-research.com/content/7/1/116
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Ethics Committee and informed consent obtained from
all subjects.
Experimental infection protocol
At an initial screening visit suitability for the study was
assessed and symptom diary cards and home spirometry
commenced. Inoculation was carried out 2 weeks after
screening on study day 0 after spirometry and nasal lavage
were performed and blood drawn for baseline serology.
The subjects were seen daily for clinical review and nasal
lavage on the 8 days post-inoculation and on day 11.
Clinic spirometry was performed on study days 4, 7 and
11. At a final visit 6 weeks after inoculation convalescent
nasal lavage and serum were collected and spirometry per-
formed.
Clinical procedures
Symptom scores
Subjects completed daily diary cards of upper and lower
respiratory tract symptoms from 2 weeks prior to until 6
weeks after the day of inoculation.
Upper respiratory tract symptoms
The scoring system and clinical criteria for a cold were
derived from Jackson et al[17]. The subjects recorded the
following symptoms on a scale of 0 (no symptoms) to 3
(severe) – sneezing, runny nose, blocked nose, sore throat
or hoarse voice, headache or face pain, generally unwell,
fever or shivery, cough. A cold was considered to be
present if 2 of the following 3 criteria were present[17]:
1. A cumulative symptom score of at least 14 over a 6-day
period.
2. The subjective impression of a cold.
3. Rhinorrhoea present on at least 3 days.
Lower respiratory tract symptoms
The most commonly adopted definitions of COPD exac-
erbations rely on identifying a worsening of the previous
stable state based on reporting of increased symp-
toms[4,18,19]. We used a scoring system (adapted from
Calverley et al[20]) with which subjects quantified the
severity of lower respiratory tract symptoms (Table 2).
Based on clinical study scoring systems an exacerbation
was defined as an increase over baseline of at least 2
points on 2 consecutive days[4,18-20]. To correct for base-
line symptoms, the mean score for each patient on days -
6 to 0 was subtracted from post-inoculation scores for
both upper and lower respiratory tract scores.
Definition of a severe exacerbation
As the primary aim of the study was to evaluate the safety
of experimental rhinovirus infection in COPD subjects,
we used the following criteria for defining a severe exacer-
bation.
1. An increase in shortness of breath score by 2 points or
more on 2 consecutive days.
2. An increase in wheeze score by 3 points or more on 2
consecutive days.
3. A fall in FEV1 or PEF of 40% or more from baseline.
4. The subject developed a subjective feeling of severe
exacerbation and wished to have treatment.
5. The study doctor decided that the subject had a severe
exacerbation and required treatment.
If any subject fulfilled any 2 of these criteria he/she would
be defined as having a severe exacerbation and would be
withdrawn from the study and treatment instituted
according to the clinical judgement of the investigators.
Virus inoculation
Details regarding the preparation and safety testing of the
RV16 inoculum used in this study have been pub-
lished[21]. The virus was diluted in a total volume of 4 ml
of 0.9% saline and inoculated via the nasal route using an
atomizer (No. 286; DeVilbiss Co., Heston UK) to spray
the virus into each nostril. The subjects were instructed to
inhale deeply through the nose simultaneously with acti-
vation of the atomizer. This procedure was repeated a
number of times until all the inoculum was instilled.
Nasal lavage
Nasal lavage was performed by instilling 2.5 mL of 0.9%
saline into each nostril, holding for 5 seconds and then
expelling into a sterile container. Samples were divided
into aliquots and frozen at -80°C until analyzed.
Spirometry
Clinic spirometry was performed on a Micromedical
MicroLab (MicroMedical, Rochester, UK) spirometer
according to BTS/ARTP guidelines[22]. At screening
spirometry was performed at baseline and 15 minutes
after administration of 200 μg salbutamol via metered
dose inhaler and large volume spacer to assess reversibil-
ity. Repeat measurements were made on the same spirom-
eter on study days 4, 7, and 11 and at 6 weeks. Subjects
carried out daily home spirometry on a portable spirome-
ter (MicroSpirometer; MicroMedical) performing 3 maxi-
mal forced expirations at the same time each day and the
highest FEV1, PEF and FVC were recorded. Baseline lung
function was taken as the mean value of the recordings on
days -6 to 0.Respiratory Research 2006, 7:116 http://respiratory-research.com/content/7/1/116
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Laboratory analysis
Virus culture
Nasal lavages were inoculated onto Ohio HeLa cell cul-
tures, and RV infection detected by presence of typical
cytopathic effect. Cultures were examined daily for up to
7 days and if no CPE was observed were passaged up to 2
times further. Cultures were regarded as negative if they
showed no cytopathic effect after the 2nd further passage.
The serotype of the cultured viruses was confirmed by
neutralization using RV16 specific antiserum (ATCC V-
105-501-558; Bethesda, MD, USA)[23]. Assessment of
antibody titre was by microneutralization test using previ-
ously published methods[21].
RNA extraction and PCR
Viral RNA was extracted from nasal lavage using the
QIAmp Viral RNA Mini Kit (Qiagen Ltd) according to the
manufacturer's instructions. Samples were analysed for
picornaviruses by a reverse transcription method with ran-
dom hexamers followed by PCR[24]. To differentiate rhi-
noviruses from other picornaviruses BglI  enzyme
restriction digestion was carried out on the amplicons
generated by RT-PCR[25]. Viral load was measured with a
real-time quantitative RT-PCR assay[16]. PCR for a panel
of other respiratory viruses was carried out as previously
described[5], together with PCR for human metapneumo-
virus adapted from published protocols[26].
Detection of cytokines
Cytokines were measured in nasal lavage using the human
cytokine 10-plex assay™ (BioSource International). Assays
were performed for IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
GM-CSF, TNF-α and IFN-γ. Fresh 0.1% dithiothreitol was
added to samples at 1:5, samples were vortexed, left for 10
minutes on ice, aliquotted and stored at -80°C. Assays
were carried according to the manufacturer's instructions
and analysed on the Luminex™ 100 system.
Statistical analysis
Data are presented as mean (SEM) values. Variables were
compared with repeated measures ANOVA or Student's t-
test. Differences were considered significant for all statisti-
cal tests at p values of less than .05. Analysis was per-
formed using GraphPad Prism version 4.00 for Windows,
GraphPad Software, San Diego California USA.
Results
The first 4 subjects who were recruited and inoculated
with 10 TCID50 of the virus inoculum achieved all 3 of the
study endpoints, and therefore the study was completed at
this dose of virus. The clinical characteristics of these sub-
jects are shown in Table 3.
Induction of symptoms
Upper respiratory tract
A clinical cold developed in all 4 subjects according to the
predetermined clinical criteria; the time course of the
upper respiratory tract symptoms is shown in Figure 1A.
Upper respiratory tract symptom scores were significantly
increased compared to baseline (ANOVA p < 0.0001) on
study days 5 to 10 with the peak of cold symptoms occur-
ring on day 7.
Lower respiratory tract
All subjects developed an increase in lower respiratory
tract symptoms that fulfilled the pre-determined criteria
for an exacerbation; the time course for lower respiratory
tract scores is shown in Figure 1B. Lower respiratory tract
symptom scores were significantly increased compared to
baseline (ANOVA p < 0.0001) on days 7 to 14, with peak
lower respiratory tract symptoms on days 10 and 11.
When the individual symptoms were analysed separately,
all five lower respiratory symptom domains increased
from baseline (Figure 2), however the increases were only
statistically significant for wheeze (ANOVA p = 0.01),
cough (ANOVA p < 0.001) and sputum production
(ANOVA p = 0.01). In terms of recovery, all symptom
domains other than sputum production had recovered to
baseline by day 20, however full recovery of sputum pro-
duction took almost 4 weeks.
Lung function
Figure 3A shows the home PEF readings expressed as a 3-
day average. Home PEF fell progressively from baseline
Table 2: Lower respiratory tract symptom scoring system.
SCORE
SYMPTOMS 0 1 2 3 4
SHORTNESS OF BREATH Not breathless On moderate exertion On mild exertion On minimal exertion At rest
WHEEZE No wheeze On moderate exertion On mild exertion On minimal exertion At rest
COUGH No cough Mild Moderate Severe
SPUTUM QUANTITY (PER 24 HRS) None Minimal (<30 ml) Moderate (30–100 ml) Large (>100 ml)
SPUTUM QUALITY None Mucoid (clear) Mucopurulent (yellow) Purulent (green)Respiratory Research 2006, 7:116 http://respiratory-research.com/content/7/1/116
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after infection, reaching a nadir of approximately 12%
reduction from baseline on days 9–11 through 21–23,
before recovering on days 24–26 (ANOVA p = 0.017). PEF
was significantly reduced on days 9–11 (p = 0.022) and
21–23 (p = 0.016). There was no statistically significant
fall in FEV1  measured on the home spirometers. The
change in FEV1 measured in clinic is shown in Figure 3B.
FEV1 fell by ~16% from a mean of 1.97L at baseline to
1.65L at infection (p = 0.046).
Cytokine measurements
Among the panel of cytokines measured in nasal lavage
fluid changes were only detected in the levels of IL-6 and
IL-8 (Figure 4). Figures 4A and 4B show the time course of
the changes in IL-6 and IL-8 levels respectively. The peak
levels of cytokines after inoculation were compared to
baseline. Mean IL-6 levels rose from 40.56 pg/ml to 381.2
pg/ml but this did not reach statistical significance (p =
0.054) (Figure 4C). There was a significant increase in IL-
8 from 44.1 pg/ml when stable to 382.8 pg/ml during
infection (p = 0.046) (Figure 4D).
Virology
All subjects had a negative PCR for picornavirus and the
panel of other respiratory viruses on nasal lavage taken on
day 0 prior to inoculation. PCR for picornavirus became
positive on day 2 in all subjects and remained positive at
day 8 (n = 4) and day 11 (n = 2). BglI digestion confirmed
in all cases that the picornavirus detected by PCR was a
rhinovirus. Co-infection was excluded by negative PCR for
the other respiratory viruses in the panel. Rhinovirus was
cultured from nasal lavage in all subjects and the serotype
confirmed to be RV16 by neutralizations with specific
RV16 antiserum. All subjects developed positive RV16-
specific serologic responses to infection. PCR on convales-
cent samples taken at 6 weeks was negative for picornavi-
rus. The results of the picornavirus quantitative PCR are
shown in Figure 5. There was an increase in viral load
(ANOVA p < 0.0001) that was significant on days 4 (p <
0.01) and 5, 6 and 7 (p < 0.05).
Safety
No subject fulfilled the criteria for a severe exacerbation or
experienced any other adverse events.
Discussion
We report the first study to experimentally infect COPD
patients with a respiratory virus. Our aim was to assess the
feasibility and safety of developing a human experimental
model of virus-induced COPD exacerbation, and to pro-
vide preliminary evidence for a causative role for virus
infection in exacerbations. We demonstrated that experi-
mental rhinovirus inoculation of subjects with underlying
COPD results in clinical colds, together with increased
lower respiratory tract symptoms and falls in PEF.
These data provide preliminary evidence of safety for this
experimental model and suggest that it is feasible to fur-
ther develop the model in larger numbers of subjects.
They also provide preliminary evidence for a causal role
for virus infections in inducing exacerbations of COPD.
In order to develop new therapies for COPD exacerba-
tions a detailed understanding of the causes of exacerba-
tions, as well as the pathogenic mechanisms is needed.
Since studying naturally occurring exacerbations is
extremely difficult, development of an experimental
model in which causation could be confirmed and in
Daily upper and lower respiratory tract scores Figure 1
Daily upper and lower respiratory tract scores. (A) Mean 
total upper respiratory tract symptom scores. Symptoms 
were significantly increased on days 5 – 10. * indicates p < 
0.05 compared to baseline. (B) Lower respiratory tract 
symptom scores. Symptoms were significantly increased on 
days 7 – 14. * indicates p < 0.05 compared to baseline. Mean 
scores on days -6 to 0 were subtracted from post-inocula-
tion scores for both upper and lower respiratory tract 
scores.
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Individual lower respiratory tract symptoms Figure 2
Individual lower respiratory tract symptoms. (A) Wheeze (p = 0.01). (B) Cough (p < 0.001). (C) Sputum production (p = 0.01). 
(D) Sputum quality (p = 0.19). (E) Shortness of breath (p = 0.82).
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which detailed clinical studies on mechanisms of disease
could be carried out, would be a major step forward.
Experimental virus infection has been used extensively in
both healthy volunteers and asthmatics to study the
pathogenesis of the common cold and virus-induced
asthma exacerbations, as well as to identify and evaluate
potential new treatments for these condi-
tions[11,13,15,27]. Respiratory virus infections are associ-
ated with between 40% and 65% of COPD exacerbations
[5-8], and rhinoviruses are the most common virus type
detected. However the safety of experimental rhinovirus
infection in COPD patients has never been evaluated.
Using a low dose of RV16 inoculum we successfully
induced colds in COPD patients. In addition to the upper
respiratory tract symptoms RV16 infection resulted in a
sustained increase in lower respiratory tract symptoms
and significant falls in lung function, typical of those seen
in naturally occurring exacerbations. Consistent with pre-
vious studies of naturally occurring exacerbations
increases in symptoms and reduction in lung function
persisted for between 2 and 4 weeks from virus inocula-
tion[28].
The changes in PEF (~12%) seen in this study were of sim-
ilar magnitude to that reported elsewhere[29]. The colds
were accompanied by evidence of viral replication and
increased pro-inflammatory cytokines in the upper respi-
ratory tract, although the increase in IL-6 levels just failed
to reach significance. As the aim of this study was prima-
rily to ascertain the feasibility and safety of RV16 inocula-
tion in COPD we did not carry out lower airway sampling
but the results from this study suggest that further studies
to evaluate the effect of rhinovirus infection on lower air-
way inflammation are warranted. Although epidemiolog-
ical studies have shown an association between virus
infection and COPD exacerbation they do not prove cau-
sation. This study provides further supportive evidence in
addition to epidemiological studies that respiratory virus
infection can cause COPD exacerbations. Given that there
is data suggesting virus-induced exacerbations are more
severe[5], development of effective antiviral strategies is
an urgent priority.
The timing of upper respiratory tract and lower respiratory
tract symptoms observed in this study may have impor-
tant implications for diagnostic epidemiology of virus
induced COPD exacerbations[5,6]. The virus load in nasal
lavage was greatest on day 4, whereas the peak lower res-
piratory tract symptoms occurred on days 10/11. Assess-
ing the relationship between virus infection and COPD
exacerbations depends on sampling for viruses when
patients report lower respiratory tract symptoms. Sam-
pling the upper respiratory tract for viruses when patients
present with lower respiratory tract symptoms may give a
falsely low detection rate, as sampling will likely occur
well after the peak of virus load has passed in the upper
respiratory tract.
This interpretation is supported by our data as only 2/4
(50%) of the subjects had positive nasal lavage PCR for
rhinoviruses on day 11. Further evidence to support this
comes from the East London COPD study in which 64%
of exacerbations were preceded by colds but a virus was
detected in only 39%[5], so the true association of respi-
ratory virus infection and COPD exacerbations is likely
even higher than reported. This may also have important
implications for therapy of virus-induced COPD exacer-
bations. The cold symptoms peaked on day 7, but were
clearly elevated as early as day 4, co-incident with the peak
in virus load, whereas lower respiratory symptoms peaked
on days 10 & 11, suggesting that if an effective antiviral or
anti-inflammatory agent were administered at the onset of
Daily and clinic spirometry measurements Figure 3
Daily and clinic spirometry measurements. (A) 3 day average 
of home-recorded PEF. There were significant falls in PEF on 
days 12 – 14 and 21 – 23. * indicates p < 0.05 compared to 
baseline. (B) FEV1 measured in clinic. There was a significant 
fall in FEV1 compared to baseline (p < 0.05).
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cold symptoms, there is a window of several days for treat-
ment to exert a beneficial effect. There is already data sug-
gesting that early treatment of exacerbations leads to
better outcomes[30] and this data should encourage
efforts to develop new treatments for exacerbations of
COPD.
An unexpected finding of this study was that all subjects
developed colds and exacerbations with 10- to 1,000-fold
lower doses of virus than used in previous studies in asth-
matic and normal volunteers[9,15]. This could suggest
that COPD patients have increased susceptibility to virus
infection, as has recently been demonstrated in asthma
[31,32]. Further studies will be needed to investigate this
interesting and potentially very important possibility.
We acknowledge that the conclusions of this study are
derived from results on only 4 subjects, however as the
pre-determined criteria for termination of the study were
reached (infection and exacerbation in 80% of 5 subjects),
we were obliged to terminate the study. We chose this
study design as previous dose-finding studies in experi-
mental virus infections have used similar patient num-
bers[33,34]. The data from this study suggests that
Levels of IL-6 and IL-8 in nasal lavage Figure 4
Levels of IL-6 and IL-8 in nasal lavage. (A) Time course of IL-6. (B) Time course of IL-8. (C) Mean levels of IL-6 in nasal lavage 
when stable and at exacerbation. There was an increase in IL-6 at exacerbation but this was not significant (p = 0.054). (D) 
Mean levels of IL-8 when stable and at exacerbation. There was a significant increase in IL-8 at exacerbation (p = 0.046).
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experimental rhinovirus infection can be used to develop
a valid and safe model of COPD exacerbation. Such a
model could overcome the many obstacles that investiga-
tors face in studying naturally occurring exacerbations
including under-reporting of exacerbations[5], delay in
presentation[30], varying aetiology, difficulties in sam-
pling the lower airway and variation in timing from onset
of exacerbation to clinical assessment and sampling.
These difficulties can all be overcome in the experimental
setting, leading to high quality, well controlled data that
is likely to take us significant steps forward in the search
for novel therapies.
Conclusion
We have shown that experimental rhinovirus infection in
COPD patients results in colds that are accompanied by
lower respiratory tract symptoms and lung function
changes typical of naturally occurring exacerbations.
These were associated with evidence of viral replication
and inflammatory cytokines in the upper airway. These
findings suggest experimental rhinovirus infection has
potential as a model of COPD exacerbation.
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